Description

Simple

Clinical

Overview

G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.

Pharmacology

Indication

Intended for the treatment of various forms of cancer.

Pharmacodynamic

G17DT is a vaccine which neutralizes the gastrin 17 (G17) hormone and glycine-extended gastrin 17. G17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid secretion. G17DT consists of a protein carrier (Diptheria Toxoid) and a synthetic peptide... Read more

Mechanism of action

When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a s... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with G17DT
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2-Methoxyethanol
The therapeutic efficacy of G17DT can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
The therapeutic efficacy of G17DT can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The therapeutic efficacy of G17DT can be decreased when used in combination with Abatacept.
Abetimus
The therapeutic efficacy of G17DT can be decreased when used in combination with Abetimus.
Acteoside
The therapeutic efficacy of G17DT can be decreased when used in combination with Acteoside.
Adalimumab
The therapeutic efficacy of G17DT can be decreased when used in combination with Adalimumab.
Afelimomab
The therapeutic efficacy of G17DT can be decreased when used in combination with Afelimomab.
Alclometasone
The therapeutic efficacy of G17DT can be decreased when used in combination with Alclometasone.
Aldesleukin
The therapeutic efficacy of G17DT can be decreased when used in combination with Aldesleukin.
Aldosterone
The therapeutic efficacy of G17DT can be decreased when used in combination with Aldosterone.
Alefacept
The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.
Alemtuzumab
The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.
Altretamine
The therapeutic efficacy of G17DT can be decreased when used in combination with Altretamine.
Amcinonide
The therapeutic efficacy of G17DT can be decreased when used in combination with Amcinonide.
Amsacrine
The therapeutic efficacy of G17DT can be decreased when used in combination with Amsacrine.
Anakinra
The therapeutic efficacy of G17DT can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)
The therapeutic efficacy of G17DT can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Apremilast
The therapeutic efficacy of G17DT can be decreased when used in combination with Apremilast.
Arsenic trioxide
The therapeutic efficacy of G17DT can be decreased when used in combination with Arsenic trioxide.
8 References
  1. 1 . Authors unspecified: Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs. 2003;17(3):223-5.PubMed: 12749761
  2. 2 . Gilliam AD, Watson SA: G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404.PubMed: 17309331
  3. 3 . Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1;106(9):1908-16.PubMed: 16568451
  4. 4 . He AR, Marshall JL: Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92.PubMed: 16613537
  5. 5 . Watson SA, Gilliam AD: G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther. 2001 Mar;1(2):309-17.PubMed: 11727538
  6. 6 . Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002 Oct 15;20(20):4225-31.PubMed: 12377966
  7. 7 . Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43.PubMed: 15135483
  8. 8 . Takhar AS, Gilliam AD, Watson SA, Henwood M, Rowlands BJ, Broome P, Beckingham IJ: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol. 2006 Mar;32(2):197-200. Epub 2005 Oct 24.PubMed: 16246519